Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | P4HB | P07237 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709269 | 1.00 | CYP1A1 (0.58) | CYP1A1CYP1B1MAOBPTPN1ALDH1A1 | |
| SCHEMBL7842668 | 0.90 | CYP1A1 (0.75) | CYP1A1CYP1B1MAOBCYP1A2HDAC3 | |
| SCHEMBL385370 | 0.89 | LMNA (0.60) | ALDH1A1LMNANPC1MAPTCA1 | |
| Ammonia Solution, Strong SCHEMBL27316369 | 0.88 | LMNA (0.59) | ALDH1A1LMNANPC1MAPTCA1 | |
| SCHEMBL31301140 | 0.86 | PTPN1 (0.73) | MAOBPTPN1ALDH1A1LMNANPC1 | |
| SCHEMBL2627847 | 0.86 | PTPN1 (0.73) | MAOBPTPN1ALDH1A1LMNANPC1 | |
| SCHEMBL71401 | 0.86 | PTPN1 (0.73) | MAOBPTPN1ALDH1A1LMNANPC1 | |
| SCHEMBL71402 | 0.86 | PTPN1 (0.73) | MAOBPTPN1ALDH1A1LMNANPC1 | |
| SCHEMBL5379059 | 0.86 | PTPN1 (0.73) | MAOBPTPN1ALDH1A1LMNANPC1 | |
| SCHEMBL13063663 | 0.84 | LMNA (0.56) | PTPN1LMNAMAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053428-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-21 | — | — | US | disclosed |
| US-20170260139-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260139-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260139-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-14 | — | — | US | disclosed |
| US-9688636-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| US-9688636-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| US-9688636-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-2875003-B1 | NEW 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS UND THEIR USE | Bayer Pharma AG (DE) | 2016-11-16 | — | — | EP | disclosed |
| US-20150148376-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| US-20150148376-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| EP-2875003-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-8981104-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-17 | — | — | US | disclosed |
| US-8981104-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-17 | — | — | US | disclosed |
| US-20140031391-A1 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031391-A1 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-30 | — | — | US | disclosed |
| WO-2014012934-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-23 | — | — | WO | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| EP-0407955-A1 | New hetrazepines acting as PAF antagonists, process for their production and their use as drugs | BOEHRINGER INGELHEIM KG (DE) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031391-A1 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use | TNNT2, TNNI3, FABP3 | CYP1A1 649/4885CYP1B1 1376/4885MAOB 937/4885 |
| US-10053428-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | TNNT2, TNNI3, FABP3 | CYP1A1 534/4885CYP1B1 1240/4885MAOB 714/4885 |
| US-20170260139-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | TNNT2, TNNI3, FABP3 | CYP1A1 649/4885CYP1B1 1376/4885MAOB 937/4885 |
| US-20150148376-A1 | NOVEL 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THEIR USE | TNNT2, TNNI3, FABP3 | CYP1A1 649/4885CYP1B1 1376/4885MAOB 937/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | CYP1A1 739/4885CYP1B1 1017/4885MAOB 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.